© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts discuss recent data results and updates happening within the HER2+ breast cancer treatment landscape.
November 30th 2021
Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.
Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.
December 13th 2021
The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.
Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.
December 14th 2021
Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.
Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.
December 21st 2021
Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.
Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.
January 4th 2022
The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.
Experts provide clinical pearls to the audience on treating patients with breast cancer.